Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder

Journal of Psychopharmacology

Volumn 26, Issue 3, 2012, Pages 360-367

  Cutler, Jessica A ^a   Rush, A John ^b   McMahon, Francis J ^a   Laje, Gonzalo ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

3 dioxygenase; depressive disorder; IDO; IDO1; IDO2; indoleamine pyrrole 2; Pharmacogenetics; treatment outcome

Indexed keywords

CITALOPRAM; INDOLEAMINE 2,3 DIOXYGENASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GENE; GENE FUNCTION; GENE LOCATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; IDO1 GENE; IDO2 GENE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; PHENOTYPE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY CLINICIAN RATED; SEQUENCE TREATMENT ALTERNATIVES TO RELIEVE DEPRESSION STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TYPES OF STUDY;

3' UNTRANSLATED REGIONS; ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG RESISTANCE; GENETIC ASSOCIATION STUDIES; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; ISOENZYMES; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; SEROTONIN UPTAKE INHIBITORS; UNITED STATES; YOUNG ADULT;

EID: 84857815702     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111434622     Document Type: Article

References (27)

1. Arefayene M, Philips S, Cao D, et al. Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity. Pharmacogenet Genomics. 2009 ; 19: 464-476
2. Browning BL, Browning SR. A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. Am J Hum Genet. 2009 ; 84: 210-223
3. Castera L, Zigante F, Bastie A, et al. Incidence of interferon alfa-induced depression in patients with chronic hepatitis C. Hepatology. 2002 ; 35: 978-979 (Pubitemid 34258398)
4. Celniker SE, Dillon LA, Gerstein MB, et al. Unlocking the secrets of the genome. Nature. 2009 ; 459: 927-930
5. Delgado PL, Charney DS, Price LH, et al. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen psychiatry. 1990 ; 47: 411-418 (Pubitemid 20161259)
6. Garriock HA, Kraft JB, Shyn SI, et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry. 2010 ; 67: 133-138
7. Heyes MP, Saito K, Major EO, et al. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3- hydroxyanthranilate. Brain. 1993 ; 116 (Pt 6). 1425-1450 (Pubitemid 24038860)
8. Laje G, Perlis RH, Rush AJ, et al. Pharmacogenetics studies in STAR*D: strengths, limitations, and results. Psychiatr Serv. 2009 ; 60: 1446-1457
9. McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006 ; 78: 804-814
10. Metz R, Duhadaway JB, Kamasani U, et al. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 2007 ; 67: 7082-7087 (Pubitemid 47206533)
11. Moresco RM, Lavazza T, Belloli S, et al. Quinolinic acid induced neurodegeneration in the striatum: a combined in vivo and in vitro analysis of receptor changes and microglia activation. Eur J Nucl Med Mol Imaging. 2008 ; 35: 704-715
12. Murray MF. The human indoleamine 2,3-dioxygenase gene and related human genes. Curr Drug Metab. 2007 ; 8: 197-200 (Pubitemid 46621669)
13. Nyholt DR. A simple correction for multiple testing for single nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet. 2004 ; 74: 765-769 (Pubitemid 38420107)
14. Paddock S, Laje G, Charney D, et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry. 2007 ; 164: 1181-1188 (Pubitemid 47292406)
15. Pierucci-Lagha A, Covault J, Bonkovsky HL, et al. A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. Psychosomatics. 2010 ; 51: 137-148
16. Poeggeler B, Rassoulpour A, Wu HQ, et al. Dopamine receptor activation reveals a novel, kynurenate-sensitive component of striatal N-methyl-D-aspartate neurotoxicity. Neuroscience. 2007 ; 148: 188-197 (Pubitemid 47211611)
17. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics. 2000a ; 155: 945-959 (Pubitemid 30397141)
18. Pritchard JK, Stephens M, Rosenberg NA, et al. Association mapping in structured populations. Am J Hum Genet. 2000b ; 67: 170-181 (Pubitemid 30481554)
19. PurcellS (2010) PLINK v1.07. Available at: http://pngu.mgh.harvard.edu/ purcell/plink/.
20. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007 ; 81: 559-575 (Pubitemid 47330214)
21. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004 ; 25: 119-142 (Pubitemid 38230109)
22. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003 ; 54: 573-583 (Pubitemid 37289444)
23. Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry. 2005 ; 66: 974-981 (Pubitemid 41191788)
24. Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004 ; 34: 73-82 (Pubitemid 38139442)
25. Tsankova NM, Berton O, Renthal W, et al. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci. 2006 ; 9: 519-525
26. Wichers MC, Koek GH, Robaeys G, et al. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry. 2005 ; 10: 538-544 (Pubitemid 40897037)
27. Wichers MC, Maes M. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci. 2004 ; 29: 11-17 (Pubitemid 38570008)